Cancer Pharma Co. Dodges Investor Stock-Drop Suit
A cancer-focused pharmaceutical company escaped a proposed shareholder class action Wednesday after a Massachusetts federal judge ruled that the company didn't mislead its investors about its financial performance and expectations....To view the full article, register now.
Already a subscriber? Click here to view full article